Vaxart

VXRT

Market cap $73M

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025.

In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study -

Question Board's Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes

Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m.

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 2025.

Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition

Urge Stockholders to Vote “AGAINST” Reverse Stock Split at Upcoming Special Meeting Call for Accountability Given Board's Pattern of Disregarding Stockholders' Will and Value-Destructive Capital Allocation Decisions ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M.

Vaxart, Inc. (OTC:VXRT) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Edward B. Berg - Senior VP & General Counsel James F.

VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09.